Preservative-free fixed-dose combination of tafluprost 0.0015% / timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: Clinical effectiveness, tolerability and safety in a real world setting (Taptiqom)

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Other
• Data sources (types), other:
  During routine visits at 4 weeks (±7 days), 12 weeks (±7 days) and 6 months (±45 days) post first Tafluprost / Timolol prescription, site staff will enter data into the eCRF covering these visits. Only data elicited as part of standard care will be entered into the eCRF.

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  Unknown